Lilly Owes Nektar $1B If It Breached Rezpeg Deal, Jury Told
Nektar Therapeutics' damages expert told a California federal jury on Thursday that Eli Lilly & Co. could owe the biotechnology company nearly $1 billion if it finds that the pharmaceutical giant...To view the full article, register now.
Already a subscriber? Click here to view full article